ALMS

Business Context and Reporting Period

Company: Alumis Inc. (ALMS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders, primarily utilizing its proprietary precision data analytics platform. Its lead product candidate is ESK-001, a second-generation TYK2 inhibitor in Phase 3 trials for plaque psoriasis and Phase 2 for systemic lupus erythematosus. The company also has a second candidate, A-005, in Phase 1 for neuroinflammatory diseases.

Key Financial Metrics

Note: Q1 2024 figures are presented for comparison; the company completed its IPO in July 2024.

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $17.4 million in license revenue in Q1 2025, compared to zero in Q1 2024. This stems from a collaboration agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of ESK-001 in Japan.
• Operating Expenses: Total operating expenses increased by 150% to $118.9 million from $47.6 million.
  • R&D Expenses: Rose 130% to $96.6 million, driven by increased clinical trial costs for ESK-001 and A-005, and higher CRO/CMO expenses.
  • G&A Expenses: Surged 296% to $22.3 million, primarily due to $7.7 million in transaction costs related to the proposed merger with ACELYRIN, Inc., and increased public company compliance costs.
• Liquidity: Cash and cash equivalents decreased by approximately $41 million during the quarter due to operating losses, partially offset by net proceeds from the maturity of marketable securities.

Guidance, Outlook, and Risks

• Merger with ACELYRIN: Alumis entered into a definitive merger agreement with ACELYRIN, Inc. in February 2025. The transaction is expected to close in Q2 2025, subject to shareholder approval and regulatory conditions. Alumis will be the accounting acquirer. Pre-merger Alumis shareholders are expected to own ~52% of the combined entity.
• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash resources ($208.7 million) are deemed insufficient to meet operating and capital requirements without additional financing or the successful closing of the merger.
• Future Funding: The company anticipates needing significant additional capital to fund R&D and operations. It plans to raise capital through equity, debt, or strategic alliances, though access is not assured.
• Clinical Outlook: The company expects to report topline results for its Phase 3 ONWARD clinical program for ESK-001 in plaque psoriasis in early Q1 2026.
• Risks: Key risks include the failure to consummate the merger, inability to raise additional capital, clinical trial failures, and regulatory delays. The company also faces risks related to the integration of ACELYRIN and potential termination fees ($10 million) if the deal fails.

Investor Verification Checklist

• Merger Status: Verify the status of shareholder approvals for the ACELYRIN merger and the expected closing timeline (Q2 2025).
• Liquidity Runway: Assess the sufficiency of the $208.7 million cash balance against the projected burn rate and the likelihood of securing additional financing if the merger is delayed.
• Revenue Sustainability: Confirm the terms of the Kaken Pharmaceutical agreement and the timing of future revenue recognition (development cost reimbursements and milestones).
• Clinical Milestones: Monitor the progress of the Phase 3 ONWARD trials for ESK-001 and the Phase 1 program for A-005.
• Expense Management: Review the trajectory of G&A expenses post-merger transaction costs and the impact of public company compliance costs.